Law360, New York (August 04, 2010, 2:21 PM ET) -- Teva Pharmaceutical Industries Ltd. has won the European Commission's blessing to proceed with its $4.93 billion purchase of German generic-drug manufacturer Ratiopharm GmbH by agreeing to a sell-off of assets in the Netherlands and Hungary.
Israel-based Teva will say goodbye to a number of Ratiopharm products, including Ratiopharm's entire distribution business in the Netherlands and the painkiller Tramadol in Hungary, in order to receive go-ahead from European regulators for the merger.
In the Netherlands, the commission found "that competition concerns would arise for a number of...
EU OKs $4.9B Teva-Ratiopharm Deal, With Caveats
To view the full article, take a free trial now.
